How much revenue did Eurofins-Cerep generate this year?
Eurofins-Cerep has achieved a revenue of 47.63 M EUR this year.
Eurofins-Cerep Revenue 2024
Eurofins-Cerep Revenue
47.63 M EUR
Ticker
ALECR.PA
ISIN
FR0013256518
WKN
A2DT0B
In 2024, Eurofins-Cerep's sales reached 47.63 M EUR, a 14.45% difference from the 41.62 M EUR sales recorded in the previous year.
The Eurofins-Cerep Revenue history
| YEAR | REVENUE (undefined EUR) | GROSS MARGIN (%) |
|---|---|---|
| 2022 | 47.63 | 86,74 |
| 2021 | 41.62 | 86,29 |
| 2020 | 32.67 | 48,49 |
| 2019 | 31.01 | 46,68 |
| 2018 | 25.45 | 49,18 |
| 2017 | 24.41 | 52,53 |
| 2016 | 23.44 | 49,32 |
| 2015 | 22.51 | 45,99 |
| 2014 | 18.5 | 41,33 |
| 2013 | 19.09 | 56,16 |
| 2012 | 17.23 | 58,39 |
| 2011 | 22.82 | 63,23 |
| 2010 | 24.65 | 57,61 |
| 2009 | 26.84 | 58,64 |
| 2008 | 31.59 | 62,90 |
| 2007 | 31.46 | 63,80 |
| 2006 | 53.17 | 63,21 |
| 2005 | 53.36 | 56,48 |
| 2004 | 51.74 | 60,84 |
| 2003 | 34.12 | 56,13 |
Eurofins-Cerep Revenue, EBIT, Net Income FR0013256518 · A2DT0B
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Eurofins-Cerep, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Eurofins-Cerep from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Eurofins-Cerep’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Eurofins-Cerep. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Eurofins-Cerep’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Eurofins-Cerep’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Eurofins-Cerep’s growth potential.
Eurofins-Cerep Revenue, EBIT and net profit per share
| Date | Eurofins-Cerep Revenue | Eurofins-Cerep EBIT | Eurofins-Cerep Net Income |
|---|---|---|---|
| 2022 | 47.63 M undefined | 11.48 M undefined | 11.52 M undefined |
| 2021 | 41.62 M undefined | 10.13 M undefined | 9.84 M undefined |
| 2020 | 32.67 M undefined | 5.54 M undefined | 5.58 M undefined |
| 2019 | 31.01 M undefined | 4.23 M undefined | 4.37 M undefined |
| 2018 | 25.45 M undefined | 2.97 M undefined | 3.86 M undefined |
| 2017 | 24.41 M undefined | 3.61 M undefined | 3.85 M undefined |
| 2016 | 23.44 M undefined | 1.63 M undefined | 2.49 M undefined |
| 2015 | 22.51 M undefined | 986,470 undefined | 1.81 M undefined |
| 2014 | 18.5 M undefined | -1.66 M undefined | -494,830 undefined |
| 2013 | 19.09 M undefined | 650,000 undefined | -880,000 undefined |
| 2012 | 17.23 M undefined | 1.62 M undefined | 320,000 undefined |
| 2011 | 22.82 M undefined | 860,000 undefined | -80,000 undefined |
| 2010 | 24.65 M undefined | -3.06 M undefined | -5.41 M undefined |
| 2009 | 26.84 M undefined | -1.72 M undefined | -2.17 M undefined |
| 2008 | 31.59 M undefined | 2.02 M undefined | -2.15 M undefined |
| 2007 | 31.46 M undefined | 3.08 M undefined | 9.16 M undefined |
| 2006 | 53.17 M undefined | -16.28 M undefined | -16.94 M undefined |
| 2005 | 53.36 M undefined | -5.93 M undefined | -6.69 M undefined |
| 2004 | 51.74 M undefined | 930,000 undefined | 2.35 M undefined |
| 2003 | 34.12 M undefined | -1.16 M undefined | 460,000 undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2003 | 34.12 M EUR | -1.16 M EUR | 460,000 EUR |
| 2004 | 51.74 M EUR | 930,000 EUR | 2.35 M EUR |
| 2005 | 53.36 M EUR | -5.93 M EUR | -6.69 M EUR |
| 2006 | 53.17 M EUR | -16.28 M EUR | -16.94 M EUR |
| 2007 | 31.46 M EUR | 3.08 M EUR | 9.16 M EUR |
| 2008 | 31.59 M EUR | 2.02 M EUR | -2.15 M EUR |
| 2009 | 26.84 M EUR | -1.72 M EUR | -2.17 M EUR |
| 2010 | 24.65 M EUR | -3.06 M EUR | -5.41 M EUR |
| 2011 | 22.82 M EUR | 860,000 EUR | -80,000 EUR |
| 2012 | 17.23 M EUR | 1.62 M EUR | 320,000 EUR |
| 2013 | 19.09 M EUR | 650,000 EUR | -880,000 EUR |
| 2014 | 18.5 M EUR | -1.66 M EUR | -494,830 EUR |
| 2015 | 22.51 M EUR | 986,470 EUR | 1.81 M EUR |
| 2016 | 23.44 M EUR | 1.63 M EUR | 2.49 M EUR |
| 2017 | 24.41 M EUR | 3.61 M EUR | 3.85 M EUR |
| 2018 | 25.45 M EUR | 2.97 M EUR | 3.86 M EUR |
| 2019 | 31.01 M EUR | 4.23 M EUR | 4.37 M EUR |
| 2020 | 32.67 M EUR | 5.54 M EUR | 5.58 M EUR |
| 2021 | 41.62 M EUR | 10.13 M EUR | 9.84 M EUR |
| 2022 | 47.63 M EUR | 11.48 M EUR | 11.52 M EUR |
Eurofins-Cerep stock margins FR0013256518 · A2DT0B
The Eurofins-Cerep margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Eurofins-Cerep. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Eurofins-Cerep.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Eurofins-Cerep's sales revenue. A higher gross margin percentage indicates that the Eurofins-Cerep retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Eurofins-Cerep's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Eurofins-Cerep's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Eurofins-Cerep's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Eurofins-Cerep. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Eurofins-Cerep's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Eurofins-Cerep Margin History
| Eurofins-Cerep Gross margin | Eurofins-Cerep Profit margin | Eurofins-Cerep EBIT margin | Eurofins-Cerep Profit margin |
|---|---|---|---|
| 2022 | 86.74 % | 24.09 % | 24.2 % |
| 2021 | 86.29 % | 24.35 % | 23.65 % |
| 2020 | 48.49 % | 16.97 % | 17.07 % |
| 2019 | 46.68 % | 13.63 % | 14.09 % |
| 2018 | 49.18 % | 11.67 % | 15.16 % |
| 2017 | 52.53 % | 14.78 % | 15.77 % |
| 2016 | 49.32 % | 6.96 % | 10.61 % |
| 2015 | 45.99 % | 4.38 % | 8.03 % |
| 2014 | 41.33 % | -8.96 % | -2.67 % |
| 2013 | 56.16 % | 3.4 % | -4.61 % |
| 2012 | 58.39 % | 9.4 % | 1.86 % |
| 2011 | 63.23 % | 3.77 % | -0.35 % |
| 2010 | 57.61 % | -12.41 % | -21.95 % |
| 2009 | 58.64 % | -6.41 % | -8.08 % |
| 2008 | 62.9 % | 6.39 % | -6.81 % |
| 2007 | 63.8 % | 9.79 % | 29.12 % |
| 2006 | 63.21 % | -30.62 % | -31.86 % |
| 2005 | 56.48 % | -11.11 % | -12.54 % |
| 2004 | 60.84 % | 1.8 % | 4.54 % |
| 2003 | 56.13 % | -3.4 % | 1.35 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2003 | 56.13 % | -3.4 % | 1.35 % |
| 2004 | 60.84 % | 1.8 % | 4.54 % |
| 2005 | 56.48 % | -11.11 % | -12.54 % |
| 2006 | 63.21 % | -30.62 % | -31.86 % |
| 2007 | 63.8 % | 9.79 % | 29.12 % |
| 2008 | 62.9 % | 6.39 % | -6.81 % |
| 2009 | 58.64 % | -6.41 % | -8.08 % |
| 2010 | 57.61 % | -12.41 % | -21.95 % |
| 2011 | 63.23 % | 3.77 % | -0.35 % |
| 2012 | 58.39 % | 9.4 % | 1.86 % |
| 2013 | 56.16 % | 3.4 % | -4.61 % |
| 2014 | 41.33 % | -8.96 % | -2.67 % |
| 2015 | 45.99 % | 4.38 % | 8.03 % |
| 2016 | 49.32 % | 6.96 % | 10.61 % |
| 2017 | 52.53 % | 14.78 % | 15.77 % |
| 2018 | 49.18 % | 11.67 % | 15.16 % |
| 2019 | 46.68 % | 13.63 % | 14.09 % |
| 2020 | 48.49 % | 16.97 % | 17.07 % |
| 2021 | 86.29 % | 24.35 % | 23.65 % |
| 2022 | 86.74 % | 24.09 % | 24.2 % |
Eurofins-Cerep Aktienanalyse
What does Eurofins-Cerep do?
Eurofins-Cerep SA is a globally renowned biotechnology company that was founded in 1993. With its headquarters in Paris, France, the company operates over 47 locations worldwide and employs over 45,000 employees. The company specializes in the development and commercialization of innovative biological technologies for use in the pharmaceutical industry. Eurofins-Cerep focuses on the discovery of new drugs for the treatment of diseases such as cancer, Alzheimer's, Parkinson's, and diabetes. The business model of Eurofins-Cerep is based on three pillars: services, product sales, and research and development offerings. Under the "services" division, the company offers extensive pharmacological and biological testing and screening procedures for drug compounds to its customers. Eurofins-Cerep has a wide range of assays and tests that allow customers to assess and optimize the efficacy and safety of their drug compounds. The "product sales" division includes the manufacturing and distribution of over 1,000 different biological reagents, antibodies, and other products for biomedical research. The company specializes in producing reagents used in drug development, such as G-protein coupled receptors (GPCRs). The third pillar of Eurofins-Cerep's business model consists of research and development services for customers and partners. The company supports customers in identifying new drug compounds and developing drug candidates up to market approval. The company has various divisions, including the Cerep division, which specializes in the evaluation of potential drug candidates and associated toxicology. The Eurofins Pharma Discovery Services division offers advanced drug optimization and screening services by providing customized approaches to drug development. The Eurofins BioPharma Services division is a leading provider of complete solutions in the pharmaceutical development and GxP laboratories. The company is also active in other areas such as the environment and the food industry. Eurofins-Cerep has made several acquisitions in the past, including the acquisition of XDS Laboratories, a leading provider of clinical laboratory services, and EAG Laboratories, a highly specialized analysis and testing service unit. Overall, Eurofins-Cerep SA has achieved numerous milestones in the past 28 years and has become one of the world's leading providers of biological screening and analysis technologies. The company remains committed to offering its customers innovative biological technologies and maintaining its reputation as a reliable partner in the pharmaceutical industry. Eurofins-Cerep ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Eurofins-Cerep's Sales Figures
The sales figures of Eurofins-Cerep originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Eurofins-Cerep’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Eurofins-Cerep's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Eurofins-Cerep’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Eurofins-Cerep stock
How much was the turnover of the company Eurofins-Cerep compared to the previous year?
The revenue of Eurofins-Cerep has increased by 14.45% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Eurofins-Cerep?
The revenue of Eurofins-Cerep is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Eurofins-Cerep measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Eurofins-Cerep so important for investors?
The revenue of Eurofins-Cerep is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Eurofins-Cerep pay?
Over the past 12 months, Eurofins-Cerep paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Eurofins-Cerep is expected to pay a dividend of 0 EUR.
What is the dividend yield of Eurofins-Cerep?
The current dividend yield of Eurofins-Cerep is .
When does Eurofins-Cerep pay dividends?
Eurofins-Cerep pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Eurofins-Cerep?
Eurofins-Cerep paid dividends every year for the past 0 years.
What is the dividend of Eurofins-Cerep?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Eurofins-Cerep located?
Eurofins-Cerep is assigned to the 'Health' sector.
Wann musste ich die Aktien von Eurofins-Cerep kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Eurofins-Cerep from 9/29/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.
When did Eurofins-Cerep pay the last dividend?
The last dividend was paid out on 9/29/2024.
What was the dividend of Eurofins-Cerep in the year 2023?
In the year 2023, Eurofins-Cerep distributed 0 EUR as dividends.
In which currency does Eurofins-Cerep pay out the dividend?
The dividends of Eurofins-Cerep are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Eurofins-Cerep
Our stock analysis for Eurofins-Cerep Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Eurofins-Cerep Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Eurofins-Cerep Revenue
- Eurofins-Cerep Net Income
- Eurofins-Cerep P/E
- Eurofins-Cerep P/S
- Eurofins-Cerep EBIT
- Eurofins-Cerep Dividend
- Eurofins-Cerep Stocks
- Eurofins-Cerep Market capitalization
- Eurofins-Cerep Debt
- Eurofins-Cerep Liabilities
- Eurofins-Cerep Equity
- Eurofins-Cerep AAQS
- Eurofins-Cerep Employees
- Eurofins-Cerep ROE
- Eurofins-Cerep ROA
- Eurofins-Cerep ROCE
